

Attorney Docket No. 08702.0005-00000
Application No. 09/816,697

IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-56. (Canceled)

57. (Previously presented) A method for identifying a compound which inhibits the binding of a SLIC-1 protein to PSGL-1, comprising:

- i) contacting said SLIC-1 protein with a test compound; and
- ii) determining the effect of the test compound on the binding of said SLIC-1 protein to PSGL-1;

wherein said SLIC-1 protein consists of:

- 1) a SLIC-1 moiety chosen from:
 - (a) amino acids 1-226 of SEQ ID NO:2;
 - (b) amino acids 1-316 of SEQ ID NO:2; and
 - (c) fragments of (a) or (b) that have PSGL-1 binding activity; and
- 2) optionally, at least one heterologous amino acid sequence.

58. (Previously presented) A method for identifying a compound which increases the binding of a SLIC-1 protein to PSGL-1, comprising:

- i) contacting said SLIC-1 protein with a test compound; and
- ii) determining the effect of the test compound on the binding of said SLIC-1 protein to PSGL-1;

wherein said SLIC-1 protein consists of:

- 1) a SLIC-1 moiety chosen from:
 - (a) amino acids 1-226 of SEQ ID NO:2;
 - (b) amino acids 1-316 of SEQ ID NO:2; and
 - (c) fragments of (a) or (b) that have PSGL-1 binding activity; and
- 2) optionally, at least one heterologous amino acid sequence.

Attorney Docket No. 08702.0005-00000
Application No. 09/816,697

59. (Previously presented) The method of claim 57, wherein at least one heterologous sequence is a protein tag.
60. (Previously presented) The method of claim 59, wherein said protein tag is a GST tag.
61. (Previously presented) The method of claim 59, wherein said protein tag is a T7 tag.
62. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of amino acids 1-226 of SEQ ID NO:2.
63. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of amino acids 1-226 of SEQ ID NO:2 and a protein tag.
64. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of amino acids 1-316 of SEQ ID NO:2.
65. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of amino acids 1-316 of SEQ ID NO:2 and a protein tag.
66. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of a fragment of amino acids 1-266 of SEQ ID NO:2, wherein said fragment has PSLG-1 binding activity.
67. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of a fragment of amino acids 1-266 of SEQ ID NO:2, wherein said fragment has PSLG-1 binding activity, and a protein tag.

Attorney Docket No. 08702.0005-00000
Application No. 09/816,697

68. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of a fragment of amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

69. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of a fragment of amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.

70. (Previously presented) The method of claim 58, wherein at least one heterologous sequence is a protein tag.

71. (Previously presented) The method of claim 70, wherein said protein tag is a GST tag.

72. (Previously presented) The method of claim 70, wherein said protein tag is a T7 tag.

73. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of amino acids 1-226 of SEQ ID NO:2.

74. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of amino acids 1-226 of SEQ ID NO:2 and a protein tag.

75. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of amino acids 1-316 of SEQ ID NO:2.

76. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of amino acids 1-316 of SEQ ID NO:2 and a protein tag.

Attorney Docket No. 08702.0005-00000
Application No. 09/816,697

77. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of a fragment of amino acids 1-266 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

78. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of a fragment of amino acids 1-266 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.

79. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of a fragment of amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

80. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of a fragment of amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.

81. (New) A method for identifying a compound which inhibits the binding of a SLIC-1 protein to PSGL-1, comprising:

- i) contacting said SLIC-1 protein with a test compound; and
- ii) determining the effect of the test compound on the binding of said SLIC-1 protein to PSGL-1;

wherein said SLIC-1 protein consists of:

- 1) a SLIC-1 moiety having PSGL-1 binding activity chosen from:
 - (a) an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2;
 - (b) an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2; and
 - (c) fragments of (a) or (b); and
- 2) optionally, at least one heterologous amino acid sequence.

Attorney Docket No. 08702.0005-00000
Application No. 09/816,697

82. (New) A method for identifying a compound which increases the binding of a SLIC-1 protein to PSGL-1, comprising:

- i) contacting said SLIC-1 protein with a test compound; and
- ii) determining the effect of the test compound on the binding of said SLIC-1 protein to PSGL-1;

wherein said SLIC-1 protein consists of:

- 1) a SLIC-1 moiety having PSGL-1 binding activity chosen from:
 - (a) an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2;
 - (b) an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2; and
 - (c) fragments of (a) or (b); and
- 2) optionally, at least one heterologous amino acid sequence.

83. (New) The method of claim 81, wherein at least one heterologous sequence is a protein tag.

84. (New) The method of claim 83, wherein said protein tag is a GST tag.

85. (New) The method of claim 83, wherein said protein tag is a T7 tag.

86. (New) The method of claim 81, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2.

87. (New) The method of claim 81, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2 and a protein tag.

88. (New) The method of claim 81, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2.

Attorney Docket No. 08702.0005-00000
Application No. 09/816,697

89. (New) The method of claim 81, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2 and a protein tag.
90. (New) The method of claim 81, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-266 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.
91. (New) The method of claim 81, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-266 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.
92. (New) The method of claim 81, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.
93. (New) The method of claim 81, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.
94. (New) The method of claim 82, wherein at least one heterologous sequence is a protein tag.
95. (New) The method of claim 94, wherein said protein tag is a GST tag.
96. (New) The method of claim 94, wherein said protein tag is a T7 tag.
97. (New) The method of claim 82, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2.

Attorney Docket No. 08702.0005-00000
Application No. 09/816,697

98. (New) The method of claim 82, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2 and a protein tag.

99. (New) The method of claim 82, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2.

100. (New) The method of claim 82, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2 and a protein tag.

101. (New) The method of claim 82, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-266 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

102. (New) The method of claim 82, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-266 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.

103. (New) The method of claim 82, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

104. (New) The method of claim 82, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.